Expert Gastric Cancer Surgery & Treatment in Shanghai
The Department of Gastric Surgery at Fudan University Shanghai Cancer Center (FUSCC) is one of China's most distinguished centers for the surgical and multidisciplinary management of gastric cancer and gastroesophageal junction (GEJ) cancer. With one of the highest volumes of gastric cancer surgery in China, the department combines outstanding surgical expertise with a world-class research program and a fully integrated multidisciplinary approach, offering international patients access to the latest minimally invasive techniques, precision oncology, and clinical trials for gastric cancer.
Gastric cancer remains one of the most common cancers in East Asia, and China accounts for a significant proportion of the global burden. FUSCC's gastric surgery department has accumulated unparalleled experience in the surgical management of all stages of gastric cancer, from early gastric cancer amenable to endoscopic or minimally invasive surgical treatment to locally advanced disease requiring extended resection and perioperative systemic therapy. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at FUSCC.
About the Department
FUSCC's gastric surgery department is a national key clinical specialty performing hundreds of gastric cancer operations annually. The department operates dedicated gastric surgical wards, a comprehensive outpatient gastric oncology clinic, a gastric cancer MDT, a minimally invasive and robotic gastric surgery program, and works in close collaboration with medical oncology, radiation oncology, endoscopy, pathology, and molecular diagnostics through a fully integrated multidisciplinary team.
Faculty members publish regularly in leading gastric oncology journals including Journal of Clinical Oncology, Annals of Oncology, Annals of Surgery, Gastric Cancer, and Cancer.
Conditions Treated
Gastric Cancer by Stage
- Early Gastric Cancer (T1a) — Endoscopic submucosal dissection (ESD) for mucosal gastric cancer meeting expanded criteria; coordination with gastroenterology endoscopy team; surveillance after ESD
- Early Gastric Cancer (T1b-T2) — Laparoscopic or robotic distal gastrectomy with D2 lymph node dissection; function-preserving gastrectomy (pylorus-preserving, proximal gastrectomy with double-tract reconstruction) for selected cases
- Locally Advanced Gastric Cancer (T3-T4, N+) — Perioperative FLOT chemotherapy (preferred) or neoadjuvant SOX/XELOX; total or distal gastrectomy with D2 lymph node dissection; adjuvant S-1 or XELOX
- HER2-Positive Gastric Cancer — Trastuzumab + chemotherapy (ToGA); trastuzumab deruxtecan (T-DXd) for HER2-positive second-line; zanidatamab for HER2-amplified
- MSI-H/dMMR Gastric Cancer — Pembrolizumab + chemotherapy (KEYNOTE-590/811); nivolumab + chemotherapy (CheckMate 649)
- PD-L1-Positive Gastric Cancer — Nivolumab + chemotherapy for CPS ≥5; pembrolizumab combinations
- CLDN18.2-Positive Gastric Cancer — Zolbetuximab + FOLFOX/CAPOX for CLDN18.2-positive, RAS wild-type metastatic gastric cancer
- FGFR2b-Amplified Gastric Cancer — Bemarituzumab + mFOLFOX6 for FGFR2b-overexpressing gastric cancer
- Metastatic Gastric Cancer — Comprehensive first and subsequent-line systemic therapy; ramucirumab + paclitaxel second-line; trifluridine/tipiracil third-line
Gastroesophageal Junction (GEJ) Cancer
- Siewert Type I GEJ Cancer — Managed as esophageal adenocarcinoma; Ivor Lewis esophagectomy; perioperative FLOT
- Siewert Type II & III GEJ Cancer — Total gastrectomy with distal esophagectomy; transhiatal or transthoracic approach; perioperative FLOT or neoadjuvant chemoradiation
Gastric Stromal Tumors (GIST)
- Resectable GIST — Laparoscopic wedge resection; R0 resection without lymph node dissection; adjuvant imatinib for intermediate/high-risk disease
- Advanced/Metastatic GIST — Imatinib first-line; sunitinib second-line; regorafenib third-line; ripretinib fourth-line; avapritinib for PDGFRA D842V-mutated GIST
Gastric Neuroendocrine Tumors
- Type I & II Gastric NETs — Endoscopic resection for small tumors; surgical resection for larger lesions
- Type III Gastric NETs & NEC — Surgical resection with lymph node dissection; platinum-etoposide for NEC
Surgical Excellence
Minimally Invasive & Robotic Gastric Surgery
FUSCC's gastric surgery department has been at the forefront of minimally invasive gastric cancer surgery in China:
- Laparoscopic Distal Gastrectomy with D2 Dissection — Standard minimally invasive approach for distal gastric cancer; Billroth I, Billroth II, and Roux-en-Y reconstruction
- Laparoscopic Total Gastrectomy with D2 Dissection — For proximal and whole-stomach gastric cancer; Roux-en-Y esophagojejunostomy
- Robotic Gastrectomy — da Vinci robotic distal and total gastrectomy with D2 dissection; enhanced precision for suprapancreatic lymph node dissection
- Laparoscopic Proximal Gastrectomy with Double-Tract Reconstruction — Function-preserving surgery for proximal early gastric cancer; reduced reflux compared to esophagogastrostomy
- Pylorus-Preserving Gastrectomy (PPG) — For middle-third early gastric cancer; preservation of pyloric function
- Reduced-Port & Single-Port Laparoscopic Gastrectomy — For cosmetically sensitive patients
Extended & Complex Gastric Surgery
- D2+ Lymph Node Dissection — Para-aortic lymph node dissection for selected locally advanced cases
- Combined Organ Resection — En bloc resection of adjacent organs (spleen, pancreatic tail, transverse colon) for T4b disease
- Conversion Surgery — Surgical resection after conversion chemotherapy for initially unresectable locally advanced or oligometastatic gastric cancer
- Cytoreductive Surgery + HIPEC — For selected patients with limited peritoneal metastases achieving good response to systemic therapy
Gastric Cancer MDT & Precision Oncology
All gastric cancer cases at FUSCC are reviewed by the gastric cancer MDT, integrating surgical, medical oncological, radiation oncological, endoscopic, radiological, and pathological expertise. The MDT's precision oncology approach includes:
- HER2 Testing — IHC and FISH for all gastric and GEJ cancer patients; HER2 re-testing at progression
- MSI/MMR Testing — IHC for MLH1, MSH2, MSH6, PMS2; PCR for MSI
- PD-L1 CPS Testing — For immunotherapy eligibility assessment
- CLDN18.2 Testing — IHC for zolbetuximab eligibility
- FGFR2b Testing — IHC and NGS for bemarituzumab eligibility
- Comprehensive NGS — For identification of rare actionable alterations and clinical trial eligibility
- Liquid Biopsy — ctDNA monitoring for treatment response and minimal residual disease
Why International Patients Choose FUSCC Gastric Surgery
- High-Volume Expertise — One of China's highest-volume gastric cancer surgery programs with outcomes benchmarked against international standards
- Minimally Invasive Leadership — Laparoscopic and robotic D2 gastrectomy as routine offerings with function-preserving options
- Novel Therapy Access — Zolbetuximab, bemarituzumab, T-DXd, and other novel agents through clinical trials and approved indications
- Conversion Surgery Expertise — Surgical resection after conversion therapy for initially unresectable disease
- Comprehensive MDT — Fully integrated multidisciplinary team with precision molecular profiling
- Cost-Effectiveness — World-class gastric cancer care at significantly lower cost than equivalent treatment in Western countries
The CMCS Patient Journey
- Initial Inquiry — Share your diagnosis, imaging (CT, PET-CT), endoscopy and biopsy reports, molecular profiling (HER2, MSI, PD-L1, CLDN18.2), and prior treatment history with CMCS.
- Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate gastric surgeon and oncologist based on your tumor stage and molecular profile.
- MDT Submission — Where appropriate, we facilitate pre-arrival case review by FUSCC's gastric cancer MDT.
- Priority Scheduling — We secure a consultation and surgical slot with minimal waiting time.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near FUSCC, and Shanghai airport transfers.
- Surgical Admission Support — Full coordination of pre-operative assessment, perioperative chemotherapy scheduling, admission, and inpatient care.
- Post-Operative Follow-Up — Pathology report translation, adjuvant therapy coordination, and remote follow-up after you return home.
Book a Consultation
If you are seeking expert gastric cancer care in Shanghai — whether for early gastric cancer, locally advanced disease, metastatic gastric cancer, GIST, or a second opinion on a gastric diagnosis — CMCS can arrange a specialist consultation with FUSCC's gastric surgery team.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 comentarios